Management of chronic diseases in the 21st century: The emerging role of specialty pharmacies

American Journal of Health-System Pharmacy

Volumn 64, Issue 22, 2007, Pages 2382-2385

  Shane, Rita ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; BETA1A INTERFERON; EFALIZUMAB; ETANERCEPT; GLATIRAMER; HUMAN GROWTH HORMONE; IMIGLUCERASE; INFLIXIMAB; INTERFERON; INTERFERON BETA SERINE; LARONIDASE; NATALIZUMAB; OMALIZUMAB; PALIVIZUMAB; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROSTACYCLIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; UNIPROST;

ANKYLOSING SPONDYLITIS; ASTHMA; CROHN DISEASE; DRUG COST; DRUG INDUSTRY; ENZYME REPLACEMENT; FABRY DISEASE; GAUCHER DISEASE; GLYCOGEN STORAGE DISEASE TYPE 2; HEALTH CARE; HEALTH CARE SYSTEM; HEPATITIS C; HOSPITAL CARE; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; JUVENILE RHEUMATOID ARTHRITIS; MEDICAID; MEDICAL ETHICS; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PULMONARY HYPERTENSION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RHEUMATOID ARTHRITIS; VIRUS INFECTION;

EID: 36448990066     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070242     Document Type: Review

References (13)

1. Implications of the specialty-drug marketplace for health-system pharmacy: a roundtable discussion. Am J Health-Syst Pharm. 2007; 64:2364-72.
2. Stern D, Reissman D. Specialty pharmacy cost management strategies of private health care payers. J Manag Care Pharm. 2006; 12:736-44.
3. Flood J, Mihalik C, Fleming RR et al. The use of therapeutic interchange for biologic therapies. Manag Care. 2007; 16:51-62.
4. Adams KT. More drugs for more uses drive specialty spending growth. www.biotechnologyhealthcare.com/journal/fulltext/3/4BH0304067.pdf (accessed 2007 Aug 8).
5. Breitbart RE. On specialty pharmaceuticals: reflections of a second-year medical student. www.biotechnologyhealthcare.com/journal/fulltext/3/5/BH0305041. pdf (accessed 2007 Aug 8).
6. American Society of Health-System Pharmacists. Restricted drug distribution system survey. www.ashp.org/s_ashp/docs/files/ GAD_ASHP_RDDS_SurveyFull0307.pdf (accessed 2007 Apr 7).
7. Silverman E. The first generation of biodrug management: to what results? www.biotechnologyhealthcare.com/journal/fulltext/3/5/BH0305030.pdf (accessed 2007 Aug 8).
8. Serono injectables digest. Vol. 1. Geneva: Serono; 2004.
9. Medel M. Six strategies to rein in rising benefit costs. Drug Benefit Trends. 2007;19:114-5.
10. Biotechnology Industry Organization. Follow-on biologies archive. www.bio.org/healthcare/followon (accessed 2006 May 21).
11. Barlas S. Opening the door to follow-on proteins? www. biotechnologyhealthcare.com/journal/fulltext/3/5/BH0305047.pdf (accessed 2007 Aug 9).
12. National Coalition on Health Care. Facts on the cost of health care. www.nchc.org/facts/cost.shtml (accessed 2007 Apr 15).
13. Nobscot Corporation. Retention management and metrics. www.nobscot.com/survey/index.cfm (accessed 2007 Apr 15).